Context-dependent roles of complement in cancer.
Journal
Nature reviews. Cancer
ISSN: 1474-1768
Titre abrégé: Nat Rev Cancer
Pays: England
ID NLM: 101124168
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
accepted:
14
09
2019
pubmed:
2
11
2019
medline:
24
12
2019
entrez:
1
11
2019
Statut:
ppublish
Résumé
The tumour microenvironment (TME) highly influences the growth and spread of tumours, thus impacting the patient's clinical outcome. In this context, the complement system plays a major and complex role. It may either act to kill antibody-coated tumour cells, support local chronic inflammation or hamper antitumour T cell responses favouring tumour progression. Recent studies demonstrate that these opposing effects are dependent upon the sites of complement activation, the composition of the TME and the tumour cell sensitivity to complement attack. In this Review, we present the evidence that has so far accrued showing a role for complement activation and its effects on cancer control and clinical outcome under different TME contexts. We also include a new analysis of the publicly available transcriptomic data to provide an overview of the prognostic value of complement gene expression in 30 cancer types. We argue that the interplay of complement components within each cancer type is unique, governed by the properties of the tumour cells and the TME. This concept is of critical importance for the design of efficient therapeutic strategies aimed at targeting complement components and their signalling.
Identifiants
pubmed: 31666715
doi: 10.1038/s41568-019-0210-0
pii: 10.1038/s41568-019-0210-0
doi:
Substances chimiques
Cancer Vaccines
0
Complement System Proteins
9007-36-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
698-715Références
Fridman, W. H., Zitvogel, L., Sautes-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).
pubmed: 28741618
doi: 10.1038/nrclinonc.2017.101
Merle, N. S., Church, S. E., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement system part I—molecular mechanisms of activation and regulation. Front. Immunol. 6, 262 (2015).
pubmed: 26082779
pmcid: 4451739
Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement system part II: role in immunity. Front. Immunol. 6, 257 (2015).
pubmed: 26074922
pmcid: 4443744
Kemper, C. & Kohl, J. Back to the future—non-canonical functions of complement. Semin. Immunol. 37, 1–3 (2018).
pubmed: 29857931
pmcid: 7470017
doi: 10.1016/j.smim.2018.05.002
Kolev, M., Le Friec, G. & Kemper, C. Complement—tapping into new sites and effector systems. Nat. Rev. Immunol. 14, 811–820 (2014).
pubmed: 25394942
doi: 10.1038/nri3761
Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A. & Lambris, J. D. Complement in cancer: untangling an intricate relationship. Nat. Rev. Immunol. 18, 5–18 (2018).
pubmed: 28920587
doi: 10.1038/nri.2017.97
Gros, P., Milder, F. J. & Janssen, B. J. Complement driven by conformational changes. Nat. Rev. Immunol. 8, 48–58 (2008).
pubmed: 18064050
doi: 10.1038/nri2231
Lalli, P. N. et al. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112, 1759–1766 (2008).
pubmed: 18567839
pmcid: 2518884
doi: 10.1182/blood-2008-04-151068
Strainic, M. G. et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4
pubmed: 18328742
pmcid: 2646383
doi: 10.1016/j.immuni.2008.02.001
Morgan, B. P., Walters, D., Serna, M. & Bubeck, D. Terminal complexes of the complement system: new structural insights and their relevance to function. Immunol. Rev. 274, 141–151 (2016).
pubmed: 27782334
doi: 10.1111/imr.12461
Fishelson, Z. & Kirschfink, M. Complement C5b-9 and cancer: mechanisms of cell damage, cancer counteractions, and approaches for intervention. Front. Immunol. 10, 752 (2019).
pubmed: 31024572
pmcid: 6467965
doi: 10.3389/fimmu.2019.00752
Rozenberg, P., Ziporen, L., Gancz, D., Saar-Ray, M. & Fishelson, Z. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9. Cell Death Dis. 9, 150 (2018).
pubmed: 29396434
pmcid: 5833442
doi: 10.1038/s41419-017-0240-z
Huber-Lang, M. et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12, 682–687 (2006).
pubmed: 16715088
doi: 10.1038/nm1419
Bekassy, Z. D. et al. Aliskiren inhibits renin-mediated complement activation. Kidney Int. 94, 689–700 (2018).
pubmed: 29884545
doi: 10.1016/j.kint.2018.04.004
Krisinger, M. J. et al. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 120, 1717–1725 (2012).
pubmed: 22802338
doi: 10.1182/blood-2012-02-412080
Medler, T. R. et al. Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy. Cancer Cell 34, 561–578.e6 (2018). This study demonstrates the pro-tumoural role of C5a, generated independently of the complement cascade in a mouse model.
pubmed: 30300579
pmcid: 6246036
doi: 10.1016/j.ccell.2018.09.003
Nitta, H. et al. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol. Rep. 32, 1715–1719 (2014).
pubmed: 25050844
doi: 10.3892/or.2014.3341
Zha, H. et al. Intracellular activation of complement C3 leads to PD-L1 antibody treatment resistance by modulating tumor-associated macrophages. Cancer Immunol.Res 7, 193–207 (2019).
pubmed: 30514794
doi: 10.1158/2326-6066.CIR-18-0272
West, E. E., Kolev, M. & Kemper, C. Complement and the regulation of T cell responses. Annu. Rev. Immunol. 36, 309–338 (2018).
pubmed: 29677470
pmcid: 7478175
doi: 10.1146/annurev-immunol-042617-053245
Hess, C. & Kemper, C. Complement-mediated regulation of metabolism and basic cellular processes. Immunity 45, 240–254 (2016).
pubmed: 27533012
pmcid: 5019180
doi: 10.1016/j.immuni.2016.08.003
Hajishengallis, G., Reis, E. S., Mastellos, D. C., Ricklin, D. & Lambris, J. D. Novel mechanisms and functions of complement. Nat. Immunol. 18, 1288–1298 (2017).
pubmed: 29144501
pmcid: 5706779
doi: 10.1038/ni.3858
Ling, G. S. et al. C1q restrains autoimmunity and viral infection by regulating CD8
pubmed: 29724957
pmcid: 6545171
doi: 10.1126/science.aao4555
Kremlitzka, M. et al. Interaction of serum-derived and internalized C3 with DNA in human B cells — a potential involvement in regulation of gene transcription. Front. Immunol. 10, 493 (2019).
pubmed: 30941132
pmcid: 6433827
doi: 10.3389/fimmu.2019.00493
Kolev, M. et al. Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses. Immunity 42, 1033–1047 (2015).
pubmed: 26084023
pmcid: 4518498
doi: 10.1016/j.immuni.2015.05.024
Arbore, G. et al. Complement receptor CD46 co-stimulates optimal human CD8
pubmed: 30305631
pmcid: 6180132
doi: 10.1038/s41467-018-06706-z
Arbore, G. et al. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4
pubmed: 27313051
pmcid: 5015487
doi: 10.1126/science.aad1210
Liszewski, M. K. et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 39, 1143–1157 (2013).
pubmed: 24315997
pmcid: 3865363
doi: 10.1016/j.immuni.2013.10.018
Elvington, M., Liszewski, M. K., Bertram, P., Kulkarni, H. S. & Atkinson, J. P. A C3(H
pubmed: 28192370
pmcid: 5330788
doi: 10.1172/JCI89412
Satyam, A. et al. Intracellular activation of complement 3 is responsible for intestinal tissue damage during mesenteric ischemia. J. Immunol. 198, 788–797 (2017).
pubmed: 27913632
doi: 10.4049/jimmunol.1502287
King, B. C. et al. Complement component C3 is highly expressed in human pancreatic islets and prevents β cell death via ATG16L1 interaction and autophagy regulation. Cell Metab. 29, 202–210 e6 (2019).
pubmed: 30293775
doi: 10.1016/j.cmet.2018.09.009
Markiewski, M. M. et al. Modulation of the antitumor immune response by complement. Nat. Immunol. 9, 1225–1235 (2008). This paper describes the discovery of the pro-tumoural role of C5a, through its effects on MDSCs.
pubmed: 18820683
pmcid: 2678913
doi: 10.1038/ni.1655
Roumenina, L. T. et al. Tumor cells highjack macrophage-produced complement C1q to promote tumor growth. Cancer Immunol. Res. 7, 1091–1105 (2019). This study demonstrates the tumour-promoting role of the classical complement pathway in renal cancer and the use of C1q and C4d staining as a prognostic marker.
pubmed: 31164356
Kwak, J. W. et al. Complement activation via a C3a receptor pathway alters CD4
pubmed: 29118090
doi: 10.1158/0008-5472.CAN-17-0240
Arshad, A. et al. Restoration of mannose-binding lectin complement activity is associated with improved outcome in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. JPEN J. Parenter. Enter. Nutr. 38, 214–219 (2014).
doi: 10.1177/0148607113476304
Ytting, H., Jensenius, J. C., Christensen, I. J., Thiel, S. & Nielsen, H. J. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand. J. Gastroenterol. 39, 674–679 (2004).
pubmed: 15370690
doi: 10.1080/00365520410005603
Frade, R. et al. Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res. 58, 2733–2736 (1998).
pubmed: 9661883
Jean, D. et al. A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res. 56, 254–258 (1996).
pubmed: 8542576
Reddel, C. J., Tan, C. W. & Chen, V. M. Thrombin generation and cancer: contributors and consequences. Cancers 11, E100 (2019).
pubmed: 30654498
doi: 10.3390/cancers11010100
Cho, M. S. et al. Complement component 3 is regulated by TWIST1 and mediates epithelial–mesenchymal transition. J. Immunol. 196, 1412–1418 (2016).
pubmed: 26718342
doi: 10.4049/jimmunol.1501886
Cho, M. S. et al. Autocrine effects of tumor-derived complement. Cell Rep. 6, 1085–1095 (2014).
pubmed: 24613353
pmcid: 4084868
doi: 10.1016/j.celrep.2014.02.014
Xi, W. et al. High level of anaphylatoxin C5a predicts poor clinical outcome in patients with clear cell renal cell carcinoma. Sci. Rep. 6, 29177 (2016).
pubmed: 27381421
pmcid: 4933887
doi: 10.1038/srep29177
Bonavita, E. et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 160, 700–714 (2015). This paper shows the impact of C5a on the macrophage phenotype in sarcoma mouse models.
pubmed: 25679762
doi: 10.1016/j.cell.2015.01.004
Nabizadeh, J. A. et al. The complement C3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4
pubmed: 27183625
doi: 10.4049/jimmunol.1600210
Janelle, V. et al. Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells. Cancer Immunol.Res 2, 200–206 (2014).
pubmed: 24778316
doi: 10.1158/2326-6066.CIR-13-0173
Wang, Y. et al. Autocrine complement inhibits IL10-dependent T-cell-mediated antitumor immunity to promote tumor progression. Cancer Discov. 6, 1022–1035 (2016).
pubmed: 27297552
pmcid: 5010476
doi: 10.1158/2159-8290.CD-15-1412
Guglietta, S. et al. Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat. Commun. 7, 11037 (2016).
pubmed: 26996437
pmcid: 4802169
doi: 10.1038/ncomms11037
Gunn, L. et al. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J. Immunol. 189, 2985–2994 (2012).
pubmed: 22914051
doi: 10.4049/jimmunol.1200846
Singel, K. L. et al. Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight 4, 122311 (2019).
pubmed: 30730851
doi: 10.1172/jci.insight.122311
Pio, R., Ajona, D., Ortiz-Espinosa, S., Mantovani, A. & Lambris, J. D. Complementing the cancer-immunity cycle. Front. Immunol. 10, 774 (2019).
pubmed: 31031765
pmcid: 6473060
doi: 10.3389/fimmu.2019.00774
Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).
pubmed: 23157435
doi: 10.1146/annurev-immunol-032712-100008
Schmidt, J., Klempp, C., Buchler, M. W. & Marten, A. Release of iC3b from apoptotic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo. Cancer Immunol. Immunother. 55, 31–38 (2006).
pubmed: 15891882
doi: 10.1007/s00262-005-0690-5
Liu, C. F. et al. Complement receptor 3 has negative impact on tumor surveillance through suppression of natural killer cell function. Front. Immunol. 8, 1602 (2017).
pubmed: 29209332
pmcid: 5702005
doi: 10.3389/fimmu.2017.01602
Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
pubmed: 22419253
doi: 10.1038/nrc3245
Kurihara, R. et al. C5a promotes migration, proliferation, and vessel formation in endothelial cells. Inflamm. Res. 59, 659–666 (2010).
pubmed: 20217457
pmcid: 2902742
doi: 10.1007/s00011-010-0178-4
Corrales, L. et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J. Immunol. 189, 4674–4683 (2012).
pubmed: 23028051
doi: 10.4049/jimmunol.1201654
Nunez-Cruz, S. et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14, 994–1004 (2012).
pubmed: 23226093
pmcid: 3514739
doi: 10.1593/neo.121262
Bandini, S. et al. Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. Oncoimmunology 2, e26137 (2013).
pubmed: 24228231
pmcid: 3820812
doi: 10.4161/onci.26137
Bulla, R. et al. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat. Commun. 7, 10346 (2016).
pubmed: 26831747
pmcid: 4740357
doi: 10.1038/ncomms10346
Singh, J., Ahmed, A. & Girardi, G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 58, 716–724 (2011).
pubmed: 21859968
doi: 10.1161/HYPERTENSIONAHA.111.175919
Bandini, S. et al. The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. Oncoimmunology 5, e1253653 (2016).
pubmed: 28123895
pmcid: 5214935
doi: 10.1080/2162402X.2016.1253653
Jourde-Chiche, N. et al. Endothelium structure and function in kidney health and disease. Nat. Rev. Nephrol. 15, 87–108 (2019).
pubmed: 30607032
doi: 10.1038/s41581-018-0098-z
Roumenina, L. T., Rayes, J., Frimat, M. & Fremeaux-Bacchi, V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol. Rev. 274, 307–329 (2016).
pubmed: 27782324
doi: 10.1111/imr.12479
Doerner, S. K. et al. High-fat diet-induced complement activation mediates intestinal inflammation and neoplasia, independent of obesity. Mol. Cancer Res. 14, 953–965 (2016).
pubmed: 27535705
pmcid: 5330314
doi: 10.1158/1541-7786.MCR-16-0153
Bouwens van der Vlis, T. A. M. et al. The complement system in glioblastoma multiforme. Acta Neuropathol. Commun. 6, 91 (2018).
pubmed: 30208949
pmcid: 6134703
doi: 10.1186/s40478-018-0591-4
Hu, W. H. et al. C5a receptor enhances hepatocellular carcinoma cell invasiveness via activating ERK1/2-mediated epithelial-mesenchymal transition. Exp. Mol. Pathol. 100, 101–108 (2016).
pubmed: 26475622
doi: 10.1016/j.yexmp.2015.10.001
Kaida, T. et al. C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA. Oncotarget 7, 84798–84809 (2016).
pubmed: 27756879
pmcid: 5356699
doi: 10.18632/oncotarget.12656
Fan, Z., Qin, J., Wang, D. & Geng, S. Complement C3a promotes proliferation, migration and stemness in cutaneous squamous cell carcinoma. J. Cell Mol. Med. 23, 3097–3107 (2019).
pubmed: 30825266
pmcid: 6484302
doi: 10.1111/jcmm.13959
Vlaicu, S. I. et al. Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer. Immunol. Res. 56, 109–121 (2013).
pubmed: 23247987
doi: 10.1007/s12026-012-8381-8
Ajona, D., Ortiz-Espinosa, S., Pio, R. & Lecanda, F. Complement in metastasis: a comp in the camp. Front. Immunol. 10, 669 (2019).
pubmed: 31001273
pmcid: 6457318
doi: 10.3389/fimmu.2019.00669
Ajona, D. et al. Blockade of the complement C5a/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects. Am. J Respir. Crit. Care Med. 197, 1164–1176 (2018).
pubmed: 29327939
pmcid: 6835094
doi: 10.1164/rccm.201703-0660OC
Vadrevu, S. K. et al. Complement C5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 74, 3454–3465 (2014).
pubmed: 24786787
doi: 10.1158/0008-5472.CAN-14-0157
Nitta, H. et al. Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes. Med. Oncol. 33, 118 (2016).
pubmed: 27688239
doi: 10.1007/s12032-016-0834-9
Boire, A. et al. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 168, 1101–1113.e13 (2017).
pubmed: 28283064
pmcid: 5405733
doi: 10.1016/j.cell.2017.02.025
Oostindie, S. C. et al. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. Haematologica 104, 1841–1852 (2019).
pubmed: 30792198
pmcid: 6717598
doi: 10.3324/haematol.2018.207266
Ajona, D. et al. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res. 64, 6310–6318 (2004).
pubmed: 15342420
doi: 10.1158/0008-5472.CAN-03-2328
Riihila, P. et al. Complement factor I promotes progression of cutaneous squamous cell carcinoma. J. Invest. Dermatol. 135, 579–588 (2015).
pubmed: 25184960
doi: 10.1038/jid.2014.376
Riihila, P. M. et al. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J. Invest. Dermatol. 134, 498–506 (2014).
pubmed: 23938460
doi: 10.1038/jid.2013.346
Spiller, O. B., Criado-Garcia, O., Rodriguez De Cordoba, S. & Morgan, B. P. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin. Exp. Immunol. 121, 234–241 (2000).
pubmed: 10931136
pmcid: 1905706
doi: 10.1046/j.1365-2249.2000.01305.x
Ajona, D., Hsu, Y. F., Corrales, L., Montuenga, L. M. & Pio, R. Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J. Immunol. 178, 5991–5998 (2007).
pubmed: 17442984
doi: 10.4049/jimmunol.178.9.5991
Bjorge, L. et al. Ascitic complement system in ovarian cancer. Br. J. Cancer 92, 895–905 (2005).
pubmed: 15726105
pmcid: 2361909
doi: 10.1038/sj.bjc.6602334
Kapka-Skrzypczak, L. et al. CD55, CD59, factor H and factor H-like 1 gene expression analysis in tumors of the ovary and corpus uteri origin. Immunol. Lett. 167, 67–71 (2015).
pubmed: 26261870
doi: 10.1016/j.imlet.2015.06.017
Okroj, M., Hsu, Y. F., Ajona, D., Pio, R. & Blom, A. M. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol. Immunol. 45, 169–179 (2008).
pubmed: 17548110
doi: 10.1016/j.molimm.2007.04.025
Sakai, N. et al. Tumorigenicity of BALB3T3 A31 cells transfected with hamster-complement-C1s cDNA. Int. J. Cancer 58, 309–313 (1994).
pubmed: 8026891
doi: 10.1002/ijc.2910580227
Block, I. et al. CFP suppresses breast cancer cell growth by TES-mediated upregulation of the transcription factor DDIT3. Oncogene 38, 4560–4573 (2019).
pubmed: 30755730
doi: 10.1038/s41388-019-0739-0
Kaur, A. et al. Human C1q induces apoptosis in an ovarian cancer cell line via tumor necrosis factor pathway. Front. Immunol. 7, 599 (2016).
pubmed: 28066412
pmcid: 5174108
doi: 10.3389/fimmu.2016.00599
Hong, Q. et al. Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLOS ONE 4, e5755 (2009).
pubmed: 19484134
pmcid: 2685983
doi: 10.1371/journal.pone.0005755
Mangogna, A. et al. Is the complement protein C1q a pro- or anti-tumorigenic factor? Bioinformatics analysis involving human carcinomas. Front. Immunol. 10, 865 (2019).
pubmed: 31130944
pmcid: 6509152
doi: 10.3389/fimmu.2019.00865
Lubbers, R., van Essen, M. F., van Kooten, C. & Trouw, L. A. Production of complement components by cells of the immune system. Clin. Exp. Immunol. 188, 183–194 (2017).
pubmed: 28249350
pmcid: 5383442
doi: 10.1111/cei.12952
Beatty, G. L. & Gladney, W. L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21, 687–692 (2015).
pubmed: 25501578
doi: 10.1158/1078-0432.CCR-14-1860
Mohme, M., Riethdorf, S. & Pantel, K. Circulating and disseminated tumour cells—mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 14, 155–167 (2017).
pubmed: 27644321
doi: 10.1038/nrclinonc.2016.144
Blok, V. T. et al. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab Invest. 80, 335–344 (2000).
pubmed: 10744069
doi: 10.1038/labinvest.3780038
Cancer Genome Atlas Research Network et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113–1120 (2013).
doi: 10.1038/ng.2764
Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. Science 357, eaan2507 (2017).
pubmed: 28818916
doi: 10.1126/science.aan2507
Buettner, R. et al. Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol. Cancer Res. 5, 823–832 (2007).
pubmed: 17699108
doi: 10.1158/1541-7786.MCR-06-0352
Ravindranath, N. M. & Shuler, C. Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas. J. Oral Pathol. Med. 35, 560–567 (2006).
pubmed: 16968237
doi: 10.1111/j.1600-0714.2006.00466.x
Junnikkala, S. et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br. J. Cancer 87, 1119–1127 (2002).
pubmed: 12402151
pmcid: 2376183
doi: 10.1038/sj.bjc.6600614
Surowiak, P. et al. CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients. Anticancer. Res. 26, 4943–4948 (2006).
pubmed: 17214367
Wilczek, E. et al. The possible role of factor H in colon cancer resistance to complement attack. Int. J. Cancer 122, 2030–2037 (2008).
pubmed: 18183578
doi: 10.1002/ijc.23238
Olcina, M. M. et al. Mutations in an innate immunity pathway are associated with poor overall survival outcomes and hypoxic signaling in cancer. Cell Rep. 25, 3721–3732.e6 (2018).
pubmed: 30590044
pmcid: 6405289
doi: 10.1016/j.celrep.2018.11.093
Okroj, M., Corrales, L., Stokowska, A., Pio, R. & Blom, A. M. Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol. Immunother. 58, 1771–1780 (2009).
pubmed: 19259664
doi: 10.1007/s00262-009-0685-8
Phillips, M. E., Rother, U. & Rother, K. Serum complement in the rejection of sarcoma I ascites tumor grafts. J. Immunol. 100, 493–500 (1968).
pubmed: 4171118
Eilber, F. R. & Morton, D. L. Demonstration in sarcoma patients of anti-tumor antibodies which fix only human complement. Nature 225, 1137–1138 (1970).
pubmed: 4984865
doi: 10.1038/2251137a0
Savola, S. et al. High expression of complement component 5 (C5) at tumor site associates with superior survival in Ewing’s sarcoma family of tumour patients. ISRN Oncol. 2011, 168712 (2011).
pubmed: 22084725
pmcid: 3196920
Liu, L., Li, W., Li, Z. & Kirschfink, M. Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death. Clin. Exp. Immunol. 169, 100–108 (2012).
pubmed: 22774984
pmcid: 3406369
doi: 10.1111/j.1365-2249.2012.04596.x
Manning, M. L., Williams, S. A., Jelinek, C. A., Kostova, M. B. & Denmeade, S. R. Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma. J. Immunol. 190, 2567–2574 (2013).
pubmed: 23401592
doi: 10.4049/jimmunol.1200856
Klikovits, T. et al. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Sci. Rep. 7, 16456 (2017).
pubmed: 29184132
pmcid: 5705645
doi: 10.1038/s41598-017-16551-7
Agostinis, C. et al. Complement protein C1q binds to hyaluronic acid in the malignant pleural mesothelioma microenvironment and promotes tumor growth. Front. Immunol. 8, 1559 (2017).
pubmed: 29209316
pmcid: 5701913
doi: 10.3389/fimmu.2017.01559
Lucas, S. D. et al. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum. Pathol. 27, 1329–1335 (1996).
pubmed: 8958307
doi: 10.1016/S0046-8177(96)90346-9
Goslings, W. R. et al. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. Invest. Ophthalmol. Vis. Sci. 37, 1884–1891 (1996).
pubmed: 8759358
Bacolod, M. D. et al. Immune infiltration, glioma stratification, and therapeutic implications. Transl. Cancer Res. 5, S652–S656 (2016).
pubmed: 30613474
doi: 10.21037/tcr.2016.10.69
Bouwens, T. A. et al. Complement activation in Glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue. J. NeuroImmunol. 278, 271–276 (2015).
pubmed: 25468776
doi: 10.1016/j.jneuroim.2014.11.016
Germain, C. et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189, 832–844 (2014). This study demonstrates that the density of B cell follicles inside tertiary lymphoid structures correlates with favourable prognosis in NSCLC and that activated intratumoural B cells produce antibodies to tumour-associated antigens.
pubmed: 24484236
doi: 10.1164/rccm.201309-1611OC
Montfort, A. et al. A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin. Cancer Res. 23, 250–262 (2017). This study demonstrates that B cells produce antitumoural antibodies in ovarian cancer.
pubmed: 27354470
doi: 10.1158/1078-0432.CCR-16-0081
Kroeger, D. R., Milne, K. & Nelson, B. H. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin. Cancer Res. 22, 3005–3015 (2016).
pubmed: 26763251
doi: 10.1158/1078-0432.CCR-15-2762
Yeong, J. et al. High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer. Front. Immunol. 9, 1209 (2018).
pubmed: 29899747
pmcid: 5988856
doi: 10.3389/fimmu.2018.01209
Kanyavuz, A., Marey-Jarossay, A., Lacroix-Desmazes, S. & Dimitrov, J. D. Breaking the law: unconventional strategies for antibody diversification. Nat. Rev. Immunol. 19, 355–368 (2019).
pubmed: 30718829
doi: 10.1038/s41577-019-0126-7
Ajona, D. et al. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer. J. Natl Cancer Inst. 105, 1385–1393 (2013). This study demonstrates that the complement activation fragment C4d can serve as a diagnostic and prognostic marker in lung cancer.
pubmed: 23940286
pmcid: 3776260
doi: 10.1093/jnci/djt205
Ajona, D. et al. Complement C4d-specific antibodies for the diagnosis of lung cancer. Oncotarget 9, 6346–6355 (2018).
pubmed: 29464077
doi: 10.18632/oncotarget.23690
Xi, W. et al. Enrichment of C5a–C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma. Oncotarget 7, 80925–80934 (2016).
pubmed: 27821813
pmcid: 5348365
doi: 10.18632/oncotarget.13108
Capello, M. et al. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat. Commun. 10, 254 (2019).
pubmed: 30651550
pmcid: 6335434
doi: 10.1038/s41467-018-08109-6
Chen, J. et al. Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer. Oncol. Lett. 6, 43–48 (2013).
pubmed: 23946775
pmcid: 3742809
doi: 10.3892/ol.2013.1326
Ginhoux, F. & Guilliams, M. Tissue-resident macrophage ontogeny and homeostasis. Immunity 44, 439–449 (2016).
pubmed: 26982352
doi: 10.1016/j.immuni.2016.02.024
Komohara, Y. et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 102, 1424–1431 (2011).
pubmed: 21453387
doi: 10.1111/j.1349-7006.2011.01945.x
Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549–555 (2002).
pubmed: 12401408
doi: 10.1016/S1471-4906(02)02302-5
Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749 e18 (2017). This article presents comprehensive analyses at the single-cell level of immune cells infiltrating renal tumours.
pubmed: 28475899
pmcid: 5422211
doi: 10.1016/j.cell.2017.04.016
Clarke, E. V., Weist, B. M., Walsh, C. M. & Tenner, A. J. Complement protein C1q bound to apoptotic cells suppresses human macrophage and dendritic cell-mediated Th17 and Th1 T cell subset proliferation. J. Leukoc. Biol. 97, 147–160 (2015).
pubmed: 25381385
doi: 10.1189/jlb.3A0614-278R
Ghebrehiwet, B. et al. Evidence that the two C1q binding membrane proteins, gC1q-R and cC1q-R, associate to form a complex. J. Immunol. 159, 1429–1436 (1997).
pubmed: 9233640
Riihila, P. et al. Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma. Br. J. Dermatol. https://doi.org/10.1111/bjd.18095 (2019).
Imamura, T. et al. Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosis. Breast Cancer 23, 876–885 (2016).
pubmed: 26494574
doi: 10.1007/s12282-015-0654-3
Chang, I. W. et al. Complement component 1, s subcomponent overexpression is an independent poor prognostic indicator in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. J. Cancer 7, 1396–1405 (2016).
pubmed: 27471555
pmcid: 4964123
doi: 10.7150/jca.15339
Nasr, S. H., Fidler, M. E. & Said, S. M. Paraffin immunofluorescence: a valuable ancillary technique in renal pathology. Kidney Int. Rep. 3, 1260–1266 (2018).
pubmed: 30450452
pmcid: 6224795
doi: 10.1016/j.ekir.2018.07.008
Ajona, D. et al. A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis. Cancer Discov. 7, 694–703 (2017). This study demonstrates that combined blockade of C5a signalling and PD1 can synergize to protect against mouse lung cancer.
pubmed: 28288993
doi: 10.1158/2159-8290.CD-16-1184
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03665129 (2018).
Ricklin, D., Mastellos, D. C., Reis, E. S. & Lambris, J. D. The renaissance of complement therapeutics. Nat. Rev. Nephrol 14, 26–47 (2018).
pubmed: 29199277
doi: 10.1038/nrneph.2017.156
Mastellos, D. C., Ricklin, D. & Lambris, J. D. Clinical promise of next-generation complement therapeutics. Nat. Rev. Drug Discovery 18, 707–729 (2019).
pubmed: 31324874
doi: 10.1038/s41573-019-0031-6
Surace, L. et al. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. Immunity 42, 767–777 (2015).
pubmed: 25888260
doi: 10.1016/j.immuni.2015.03.009
Facciabene, A. et al. Local endothelial complement activation reverses endothelial quiescence, enabling T-cell homing, and tumor control during T-cell immunotherapy. Oncoimmunology 6, e1326442 (2017).
pubmed: 28932632
pmcid: 5599081
doi: 10.1080/2162402X.2017.1326442
Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343, 1260–1263 (2014). This study demonstrates that the most efficient C1q binding and complement activation can be achieved if IgG hexamerizes upon binding to antigen. This concept is being used as an emerging novel strategy for antibodies engaging complement as an anticancer therapy.
pubmed: 24626930
pmcid: 4250092
doi: 10.1126/science.1248943
de Jong, R. N. et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IGg hexamers at the cell surface. PLOS Biol 14, e1002344 (2016).
pubmed: 26736041
pmcid: 4703389
doi: 10.1371/journal.pbio.1002344
Lee, C. H. et al. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions. Nat. Immunol. 18, 889–898 (2017).
pubmed: 28604720
pmcid: 6015732
doi: 10.1038/ni.3770
Bohlson, S. S., Garred, P., Kemper, C. & Tenner, A. J. Complement nomenclature-deconvoluted. Front. Immunol. 10, 1308 (2019).
pubmed: 31231398
pmcid: 6568193
doi: 10.3389/fimmu.2019.01308
Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304.e6 (2018).
pubmed: 29625048
pmcid: 5957518
doi: 10.1016/j.cell.2018.03.022
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
pubmed: 22588877
doi: 10.1158/2159-8290.CD-12-0095
Tang, Z. et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98–W102 (2017).
pubmed: 28407145
pmcid: 5570223
doi: 10.1093/nar/gkx247
Piao, C. et al. Complement 5a stimulates macrophage polarization and contributes to tumor metastases of colon cancer. Exp. Cell Res. 366, 127–138 (2018).
pubmed: 29551360
doi: 10.1016/j.yexcr.2018.03.009
Magrini, E. & Garlanda, C. Pro-tumoral role of complement activation in murine sarcoma models. Presented at the 12th International Conference on Complement Therapeutics (2019).
Riihilä et al. Complement component C3 and complement factor B promote growth of cutaneous squamous cell carcinoma. Am. J. Pathol. 1871, 1186–1197 (2017).
doi: 10.1016/j.ajpath.2017.01.006
Aykut, B. et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature 574, 264–267 (2019).
pubmed: 31578522
pmcid: 6858566
doi: 10.1038/s41586-019-1608-2